{"transactions":[{"id":1472992,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":1,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T20:10:27.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":23944,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 23,944 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2025."}],"balance_after":23944,"derivative":{"exercise_price":22.86,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":23944},"source":{"system":"sec-edgar","filing":"0001140361-24-030727","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036124030727/form4.xml","form_type":"4"}},{"id":1844111,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":1,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T23:48:03.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":25850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 25,850 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 22, 2024."}],"balance_after":25850,"derivative":{"exercise_price":21.56,"expiration_date":"2033-06-22","underlying":"Common Stock","underlying_shares":25850},"source":{"system":"sec-edgar","filing":"0001140361-23-031532","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036123031532/form4.xml","form_type":"4"}},{"id":2231310,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":1,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-16T01:07:33.000Z","date":"2022-06-13","kind":"grant","acquired":true,"shares":47745,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 47,745 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2023."}],"balance_after":47745,"derivative":{"exercise_price":10.77,"expiration_date":"2032-06-13","underlying":"Common Stock","underlying_shares":47745},"source":{"system":"sec-edgar","filing":"0001140361-22-023150","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036122023150/form4.xml","form_type":"4"}},{"id":2585108,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":27749,"kind":"person","name":"WONG RODERICK","position":1,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":2,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":3,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-31T23:11:51.000Z","date":"2021-08-27","kind":"grant","acquired":true,"shares":812516,"price":32.48,"value":26390519.68,"ownership":{"direct":false,"nature":"By RTW"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of common stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP (\"RTW\"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited, which are investment funds managed by RTW, (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW and who is a director of the Issuer and Chairman of the Issuer's Board of Directors, and (iii) Naveen Yalamanchi, M.D., who serves as a Partner and Portfolio Manager of RTW and who is a director of the Issuer. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed be the beneficial owner of securities owned or controlled by RTW."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Both Dr. Wong and Dr. Yalamanchi have a pecuniary interest in securities held by RTW. Drs. Wong and Yalamanchi disclaim beneficial ownership of the shares of common stock of the Issuer beneficially held by RTW, except to the extent of their pecuniary interest therein. The shares reported above exclude 82,391 shares of common stock indirectly beneficially held by Dr. Yalamanchi through a trust."}],"balance_after":16272635,"source":{"system":"sec-edgar","filing":"0000899243-21-034630","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000089924321034630/doc4.xml","form_type":"4"}},{"id":2666007,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":1,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-16T23:50:42.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":12236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 12,236 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 14, 2022."}],"balance_after":12236,"derivative":{"exercise_price":47.25,"expiration_date":"2031-06-14","underlying":"Common Stock","underlying_shares":12236},"source":{"system":"sec-edgar","filing":"0001140361-21-021287","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036121021287/form4.xml","form_type":"4"}},{"id":2714410,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":3,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Equity Swap (Obligation to Buy) 1)","published_at":"2021-05-13T23:49:36.000Z","date":"2021-05-11","kind":"other","acquired":true,"shares":1,"ownership":{"direct":false,"nature":"By RTW"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On May 11, 2021, an investment fund managed by RTW entered into an equity swap agreement with a third party. The reported equity swaps were on 1,000,000 shares of Common Stock of the Issuer. Under the equity swap, the fund will be obligated to pay to the third party any depreciation of the reference shares between the trade date and maturity, plus an accruing funding charge, and the third party will be obligated to pay to the fund any appreciation of the reference shares between the trade date and maturity, minus an accruing funding charge. The equity swaps expire on September 16, 2024, subject to extension."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On May 11, 2021, an investment fund managed by RTW entered into an equity swap agreement with a third party. The reported equity swaps were on 1,000,000 shares of Common Stock of the Issuer. Under the equity swap, the fund will be obligated to pay to the third party any depreciation of the reference shares between the trade date and maturity, plus an accruing funding charge, and the third party will be obligated to pay to the fund any appreciation of the reference shares between the trade date and maturity, minus an accruing funding charge. The equity swaps expire on September 16, 2024, subject to extension."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On May 11, 2021, an investment fund managed by RTW entered into an equity swap agreement with a third party. The reported equity swaps were on 1,000,000 shares of Common Stock of the Issuer. Under the equity swap, the fund will be obligated to pay to the third party any depreciation of the reference shares between the trade date and maturity, plus an accruing funding charge, and the third party will be obligated to pay to the fund any appreciation of the reference shares between the trade date and maturity, minus an accruing funding charge. The equity swaps expire on September 16, 2024, subject to extension."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On May 11, 2021, an investment fund managed by RTW entered into an equity swap agreement with a third party. The reported equity swaps were on 1,000,000 shares of Common Stock of the Issuer. Under the equity swap, the fund will be obligated to pay to the third party any depreciation of the reference shares between the trade date and maturity, plus an accruing funding charge, and the third party will be obligated to pay to the fund any appreciation of the reference shares between the trade date and maturity, minus an accruing funding charge. The equity swaps expire on September 16, 2024, subject to extension."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW, which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited, which are investment funds managed by RTW, (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW and who is a director of the Issuer and Chairman of the Issuer's Board of Directors, and (iii) Naveen Yalamanchi, M.D., who serves as a Partner and Portfolio Manager of RTW and who is a director of the Issuer. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed be the beneficial owner of securities owned or controlled by RTW."}],"balance_after":1000000,"derivative":{"exercise_price":40.0324,"underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001493152-21-011359","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000149315221011359/ownership.xml","form_type":"4"}},{"id":2714409,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":3,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-13T23:49:36.000Z","date":"2021-05-11","kind":"sale","acquired":false,"shares":725000,"price":40.0324,"value":29023490.0,"ownership":{"direct":false,"nature":"By RTW"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 is being filed in connection with the sale of the Issuer's Common Stock by an investment fund managed by RTW Investments, LP (\"RTW\") and the equity swap transactions described below entered into by another investment fund managed by RTW, to increase the funds' aggregate economic exposure to the Issuer and rebalance holdings between the funds. As a result of these transactions, the aggregate pecuniary interest of the funds has increased by 275,000 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW, which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Venture Fund Limited, which are investment funds managed by RTW, (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW and who is a director of the Issuer and Chairman of the Issuer's Board of Directors, and (iii) Naveen Yalamanchi, M.D., who serves as a Partner and Portfolio Manager of RTW and who is a director of the Issuer. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed be the beneficial owner of securities owned or controlled by RTW."}],"balance_after":15460119,"source":{"system":"sec-edgar","filing":"0001493152-21-011359","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000149315221011359/ownership.xml","form_type":"4"}},{"id":2769283,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":3,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-30T00:01:18.000Z","date":"2021-03-24","kind":"other","acquired":false,"shares":1344925,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities were held by RTW Special Purpose Fund II, LLC (\"SPF II\"). RTW Investments, LP (\"RTW\") is the investment manager of SPF II. Roderick Wong, M.D., is the Managing Partner and Chief Investment Officer of RTW and is a director of the Issuer and Chairman of the Issuer's Board of Directors. Naveen Yalamanchi, M.D., is a Partner and Portfolio Manager of RTW and is a director of the Issuer. On March 24, 2021, SPF II made an in-kind distribution of the reported securities to its non-managing members. The distribution was consistent with SPF II's operating agreement and was made on a pro rata basis to all non-managing SPF II members. No consideration was received by the Reporting Persons in connection with such distribution. The Reporting Persons did not have any pecuniary interest in the Common Stock distributed by SPF II."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were held by RTW Special Purpose Fund II, LLC (\"SPF II\"). RTW Investments, LP (\"RTW\") is the investment manager of SPF II. Roderick Wong, M.D., is the Managing Partner and Chief Investment Officer of RTW and is a director of the Issuer and Chairman of the Issuer's Board of Directors. Naveen Yalamanchi, M.D., is a Partner and Portfolio Manager of RTW and is a director of the Issuer. On March 24, 2021, SPF II made an in-kind distribution of the reported securities to its non-managing members. The distribution was consistent with SPF II's operating agreement and was made on a pro rata basis to all non-managing SPF II members. No consideration was received by the Reporting Persons in connection with such distribution. The Reporting Persons did not have any pecuniary interest in the Common Stock distributed by SPF II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities were held by RTW Special Purpose Fund II, LLC (\"SPF II\"). RTW Investments, LP (\"RTW\") is the investment manager of SPF II. Roderick Wong, M.D., is the Managing Partner and Chief Investment Officer of RTW and is a director of the Issuer and Chairman of the Issuer's Board of Directors. Naveen Yalamanchi, M.D., is a Partner and Portfolio Manager of RTW and is a director of the Issuer. On March 24, 2021, SPF II made an in-kind distribution of the reported securities to its non-managing members. The distribution was consistent with SPF II's operating agreement and was made on a pro rata basis to all non-managing SPF II members. No consideration was received by the Reporting Persons in connection with such distribution. The Reporting Persons did not have any pecuniary interest in the Common Stock distributed by SPF II."}],"balance_after":16185119,"source":{"system":"sec-edgar","filing":"0001493152-21-007119","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000149315221007119/ownership.xml","form_type":"4"}},{"id":2858705,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":1,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-02-17T02:54:01.000Z","date":"2020-12-02","kind":"gift","acquired":false,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"The Naveen Yalmanchi Revocable Living Trust, February 9, 2016"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Excludes 17,530,044 shares beneficially owned by each of (i) RTW Investments, LP (\"RTW\"), which is deemed the beneficial owner of the shares held by RTW Master Fund, Ltd., RTW Venture Fund Limited and RTW Special Purpose Fund II, LLC, which are investment funds managed by RTW, and (ii) Roderick Wong, M.D., who serves as the Managing Partner of Chief Investment Officer of RTW and who is a director of the Issuer and Chairman of the Issuer's Board of Directors, in which Dr. Yalamanchi has a pecuniary interest.  Dr. Yalamanchi disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":82391,"source":{"system":"sec-edgar","filing":"0001140361-21-005123","document":"form5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036121005123/form5.xml","form_type":"5"}},{"id":2946567,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":3,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-15T00:19:01.000Z","date":"2020-12-10","kind":"purchase","acquired":true,"shares":247720,"price":56,"value":13872320.0,"ownership":{"direct":false,"nature":"By RTW"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of common stock purchased from the underwriters pursuant to an underwritten public offering by the Issuer (the \"Offering\") at the public offering price of $56.00 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP (\"RTW\"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., RTW Special Purpose Fund II, LLC and RTW Venture Fund Limited, which are investment funds managed by RTW, (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW and who is a director of the Issuer and Chairman of the Issuer's Board of Directors, and (iii) Naveen Yalamanchi, M.D., who serves as a Partner and Portfolio Manager of RTW and who is a director of the Issuer. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed be the beneficial owner of securities owned or controlled by RTW."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Both Dr. Wong and Dr. Yalamanchi have a pecuniary interest in securities held by RTW. Each of RTW, Dr. Wong and Dr. Yalamanchi disclaims beneficial ownership of the shares of common stock of the Issuer beneficially held by RTW, except to the extent of its or his pecuniary interest therein. The shares reported above exclude (i) 82,391 shares of common stock indirectly beneficially held by Dr. Yalamanchi through the Naveen Yalamanchi Revocable Living Trust, February 9, 2016 (the \"Yalamanchi Trust\"); and (ii) 31,250 shares of common stock indirectly beneficially held by Dr. Yalamanchi through and previously gifted to the Yalamanchi Family Foundation by the Yalamanchi Trust."}],"balance_after":17530044,"source":{"system":"sec-edgar","filing":"0001493152-20-023575","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000149315220023575/ownership.xml","form_type":"4"}},{"id":3105282,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":1,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T01:38:05.000Z","date":"2020-06-16","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 16, 2021."}],"balance_after":20000,"derivative":{"exercise_price":19.9,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001140361-20-014237","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036120014237/form4.xml","form_type":"4"}},{"id":3343634,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":3,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-12T20:43:40.000Z","date":"2019-12-10","kind":"purchase","acquired":true,"shares":225000,"price":22.25,"value":5006250.0,"ownership":{"direct":false,"nature":"By RTW"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of common stock purchased from the underwriters pursuant to an underwritten public offering by the Issuer (the \"Offering\") at the public offering price of $22.25 per share. The Offering is expected to close on December 13, 2019."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP (\"RTW\"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., RTW Special Purpose Fund II, LLC and RTW Venture Fund Limited, which are investment funds managed by RTW, (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW and who is a director of the Issuer and Chairman of the Issuer's Board of Directors, and (iii) Naveen Yalamanchi, M.D., who serves as a Partner and Portfolio Manager of RTW and who is a director of the Issuer. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed be the beneficial owner of securities owned or controlled by RTW."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Both Dr. Wong and Dr. Yalamanchi have a pecuniary interest in securities held by RTW. Each of RTW, Dr. Wong and Dr. Yalamanchi disclaims beneficial ownership of the shares of common stock of the Issuer beneficially held by RTW, except to the extent of its or his pecuniary interest therein. The shares reported above exclude 113,641 shares of common stock indirectly beneficially held by Dr. Yalamanchi through the Naveen Yalamanchi Revocable Living Trust, February 9, 2016."}],"balance_after":17282324,"source":{"system":"sec-edgar","filing":"0001493152-19-019095","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000149315219019095/ownership.xml","form_type":"4"}},{"id":3552711,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"ten_percent_owner":true}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"ten_percent_owner":true}},{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":3,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-04-18T20:14:34.000Z","date":"2019-04-16","kind":"purchase","acquired":true,"shares":550005,"price":17.5,"value":9625087.5,"ownership":{"direct":false,"nature":"By RTW"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares of common stock purchased from the underwriters pursuant to an underwritten public offering by the Issuer (the \"Offering\"). The Offering closed on April 18, 2019 and the shares were purchased at the public offering price of $17.50 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP (\"RTW\"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Special Purpose Fund I, LLC (collectively, the \"Funds\"), which are investment funds managed by RTW, (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW and who is a director of the Issuer and Chairman of the Issuer's Board of Directors, and (iii) Naveen Yalamanchi, M.D., who serves as a Partner and Portfolio Manager of RTW and who is a director of the Issuer. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed be the beneficial owner of securities owned or controlled by RTW."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Both Dr. Wong and Dr. Yalamanchi have a pecuniary interest in securities held by RTW. Dr. Yalamanchi disclaims beneficial ownership of the shares of common stock of the Issuer beneficially held by RTW, except to the extent of his pecuniary interest therein. The shares reported above exclude 113,641 shares of common stock indirectly beneficially held by Dr. Yalamanchi through the Naveen Yalamanchi Revocable Living Trust, February 9, 2016."}],"balance_after":17057324,"source":{"system":"sec-edgar","filing":"0001140361-19-007331","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000114036119007331/form4.xml","form_type":"4"}},{"id":3682489,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":1,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-30T23:33:39.000Z","date":"2019-01-28","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 30,000 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on January 28, 2020."}],"balance_after":30000,"derivative":{"exercise_price":14.56,"expiration_date":"2029-01-28","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-19-002005","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036119002005/form4.xml","form_type":"4"}},{"id":3716889,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":27749,"kind":"person","name":"WONG RODERICK","position":1,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"ten_percent_owner":true}},{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":2,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"ten_percent_owner":true}},{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":3,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-12-28T22:43:10.000Z","date":"2018-12-28","kind":"grant","acquired":true,"shares":100000,"price":13.93,"value":1393000.0,"ownership":{"direct":false,"nature":"By RTW"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of common stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP (\"RTW\"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Special Purpose Fund I, LLC (collectively, the \"Funds\"), which are investment funds managed by RTW, (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW and who is a director of the Issuer and Chairman of the Issuer's Board of Directors, and (iii) Naveen Yalamanchi, M.D., who serves as a Partner and Portfolio Manager of RTW and who is a director of the Issuer. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed be the beneficial owner of securities owned or controlled by RTW."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Both Dr. Wong and Dr. Yalamanchi have a pecuniary interest in securities held by RTW. Dr. Yalamanchi disclaims beneficial ownership of the shares of common stock of the Issuer beneficially held by RTW, except to the extent of his pecuniary interest therein. The shares reported above exclude 113,641 shares of common stock indirectly beneficially held by Dr. Yalamanchi through the Naveen Yalamanchi Revocable Living Trust, February 9, 2016."}],"balance_after":16507319,"source":{"system":"sec-edgar","filing":"0001140361-18-046034","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000114036118046034/form4.xml","form_type":"4"}},{"id":3748822,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":27749,"kind":"person","name":"WONG RODERICK","position":1,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"ten_percent_owner":true}},{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":2,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":true,"ten_percent_owner":true}},{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":3,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-11-29T23:02:03.000Z","date":"2018-11-27","kind":"grant","acquired":true,"shares":967742,"price":15.5,"value":15000001.0,"ownership":{"direct":false,"nature":"By RTW"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of common stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP (\"RTW\"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Special Purpose Fund I, LLC (collectively, the \"Funds\"), which are investment funds managed by RTW, (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW and who is a director of the Issuer and Chairman of the Issuer's Board of Directors, and (iii) Naveen Yalamanchi, M.D., who serves as a Partner and Portfolio Manager of RTW and who is a director of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed be the beneficial owner of securities owned or controlled by RTW. Both Dr. Wong and Dr. Yalamanchi have a pecuniary interest in securities held by RTW. Dr. Yalamanchi disclaims beneficial ownership of the shares of common stock of the Issuer beneficially held by RTW, except to the extent of his pecuniary interest therein. The shares reported above exclude 113,641 shares of common stock indirectly beneficially held by Dr. Yalamanchi through the Naveen Yalamanchi Revocable Living Trust, February 9, 2016."}],"balance_after":16407319,"source":{"system":"sec-edgar","filing":"0001140361-18-044107","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000114036118044107/form4.xml","form_type":"4"}},{"id":3830428,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"ten_percent_owner":true}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"ten_percent_owner":true}},{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":3,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true}}],"security":"Equity Swap (Obligation to Buy)","published_at":"2018-08-29T22:48:12.000Z","date":"2018-08-27","kind":"other","acquired":true,"shares":1,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is being filed in connection with the equity swap transactions described below, which represent ordinary course rebalancing transactions in which the Funds (as defined below) entered into equity swap agreements to rebalance holdings between the Funds. After the transactions reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On August 27, 2018, RTW Master Fund, Ltd. entered into an equity swap agreement with the same a third party. The reported equity swap was on a basket of securities, which included 500,000 shares of Common Stock of the Issuer. Under the equity swap, RTW Master Fund, Ltd. will be obligated to pay to the third party any appreciation of the basket of reference shares between the trade date and maturity, plus an accruing funding charge, and the third party will be obligated to pay to RTW Master Fund, Ltd. any depreciation of the basket of reference shares between the trade date and maturity, minus an accruing funding charge. The equity swap expires on August 27, 2023, subject to extension."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On August 27, 2018, RTW Master Fund, Ltd. entered into an equity swap agreement with the same a third party. The reported equity swap was on a basket of securities, which included 500,000 shares of Common Stock of the Issuer. Under the equity swap, RTW Master Fund, Ltd. will be obligated to pay to the third party any appreciation of the basket of reference shares between the trade date and maturity, plus an accruing funding charge, and the third party will be obligated to pay to RTW Master Fund, Ltd. any depreciation of the basket of reference shares between the trade date and maturity, minus an accruing funding charge. The equity swap expires on August 27, 2023, subject to extension."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On August 27, 2018, RTW Master Fund, Ltd. entered into an equity swap agreement with the same a third party. The reported equity swap was on a basket of securities, which included 500,000 shares of Common Stock of the Issuer. Under the equity swap, RTW Master Fund, Ltd. will be obligated to pay to the third party any appreciation of the basket of reference shares between the trade date and maturity, plus an accruing funding charge, and the third party will be obligated to pay to RTW Master Fund, Ltd. any depreciation of the basket of reference shares between the trade date and maturity, minus an accruing funding charge. The equity swap expires on August 27, 2023, subject to extension."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On August 27, 2018, RTW Master Fund, Ltd. entered into an equity swap agreement with the same a third party. The reported equity swap was on a basket of securities, which included 500,000 shares of Common Stock of the Issuer. Under the equity swap, RTW Master Fund, Ltd. will be obligated to pay to the third party any appreciation of the basket of reference shares between the trade date and maturity, plus an accruing funding charge, and the third party will be obligated to pay to RTW Master Fund, Ltd. any depreciation of the basket of reference shares between the trade date and maturity, minus an accruing funding charge. The equity swap expires on August 27, 2023, subject to extension."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed in connection with the equity swap transactions described below, which represent ordinary course rebalancing transactions in which the Funds (as defined below) entered into equity swap agreements to rebalance holdings between the Funds. After the transactions reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP (\"RTW\"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd. and RTW Innovation Master Fund, Ltd. (collectively, the \"Funds\"), which are investment funds managed by RTW, (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW and who is a director of the Issuer and Chairman of the Issuer's Board of Directors, and (iii) Naveen Yalamanchi, M.D., who serves as a Partner and Portfolio Manager of RTW and who is a director of the Issuer. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed be the beneficial owner of securities owned or controlled by RTW."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(continued from Footnote 4) Both Dr. Wong and Dr. Yalamanchi have a pecuniary interest in securities held by RTW. Dr. Yalamanchi disclaims beneficial ownership of the shares of common stock of the Issuer beneficially held by RTW, except to the extent of his pecuniary interest therein."}],"balance_after":1,"derivative":{"exercise_price":22.05,"underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001140361-18-037296","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000114036118037296/form4.xml","form_type":"4"}},{"id":3830427,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"ten_percent_owner":true}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":true,"ten_percent_owner":true}},{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":3,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true}}],"security":"Equity Swap (Obligation to Sell)","published_at":"2018-08-29T22:48:12.000Z","date":"2018-08-27","kind":"other","acquired":true,"shares":1,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is being filed in connection with the equity swap transactions described below, which represent ordinary course rebalancing transactions in which the Funds (as defined below) entered into equity swap agreements to rebalance holdings between the Funds. After the transactions reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 27, 2018, RTW Innovation Master Fund, Ltd. entered into an equity swap agreement with a third party. The reported equity swap was on 500,000 shares of Common Stock of the Issuer. Under the equity swap, RTW Innovation Master Fund, Ltd. will be obligated to pay to the third party any depreciation of the reference shares between the trade date and maturity, plus an accruing funding charge, and the third party will be obligated to pay to RTW Innovation Master Fund, Ltd. any appreciation of the reference shares between the trade date and maturity, minus an accruing funding charge.  The equity swap expires on August 27, 2023, subject to extension."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 27, 2018, RTW Innovation Master Fund, Ltd. entered into an equity swap agreement with a third party. The reported equity swap was on 500,000 shares of Common Stock of the Issuer. Under the equity swap, RTW Innovation Master Fund, Ltd. will be obligated to pay to the third party any depreciation of the reference shares between the trade date and maturity, plus an accruing funding charge, and the third party will be obligated to pay to RTW Innovation Master Fund, Ltd. any appreciation of the reference shares between the trade date and maturity, minus an accruing funding charge.  The equity swap expires on August 27, 2023, subject to extension."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On August 27, 2018, RTW Innovation Master Fund, Ltd. entered into an equity swap agreement with a third party. The reported equity swap was on 500,000 shares of Common Stock of the Issuer. Under the equity swap, RTW Innovation Master Fund, Ltd. will be obligated to pay to the third party any depreciation of the reference shares between the trade date and maturity, plus an accruing funding charge, and the third party will be obligated to pay to RTW Innovation Master Fund, Ltd. any appreciation of the reference shares between the trade date and maturity, minus an accruing funding charge.  The equity swap expires on August 27, 2023, subject to extension."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On August 27, 2018, RTW Innovation Master Fund, Ltd. entered into an equity swap agreement with a third party. The reported equity swap was on 500,000 shares of Common Stock of the Issuer. Under the equity swap, RTW Innovation Master Fund, Ltd. will be obligated to pay to the third party any depreciation of the reference shares between the trade date and maturity, plus an accruing funding charge, and the third party will be obligated to pay to RTW Innovation Master Fund, Ltd. any appreciation of the reference shares between the trade date and maturity, minus an accruing funding charge.  The equity swap expires on August 27, 2023, subject to extension."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"This Form 4 is being filed in connection with the equity swap transactions described below, which represent ordinary course rebalancing transactions in which the Funds (as defined below) entered into equity swap agreements to rebalance holdings between the Funds. After the transactions reported herein, the amount of Common Stock of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP (\"RTW\"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd. and RTW Innovation Master Fund, Ltd. (collectively, the \"Funds\"), which are investment funds managed by RTW, (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW and who is a director of the Issuer and Chairman of the Issuer's Board of Directors, and (iii) Naveen Yalamanchi, M.D., who serves as a Partner and Portfolio Manager of RTW and who is a director of the Issuer. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed be the beneficial owner of securities owned or controlled by RTW."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(continued from Footnote 4) Both Dr. Wong and Dr. Yalamanchi have a pecuniary interest in securities held by RTW. Dr. Yalamanchi disclaims beneficial ownership of the shares of common stock of the Issuer beneficially held by RTW, except to the extent of his pecuniary interest therein."}],"balance_after":1,"derivative":{"exercise_price":22.05,"underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001140361-18-037296","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000114036118037296/form4.xml","form_type":"4"}},{"id":3852998,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":1,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-08-03T23:03:56.000Z","date":"2018-08-01","kind":"sale","acquired":false,"shares":637,"price":22,"value":14014.0,"ownership":{"direct":false,"nature":"Through the Naveen Yalamanchi Revocable Living Trust, February 9, 2016"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into by Dr. Yalamanchi dated as of July 10, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Excludes 15,439,577 shares beneficially owned by each of (i) RTW Investments, LP (\"RTW\"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd. and RTW Special Purpose Fund I, LLC, which are investment funds managed by RTW, and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW and who is a director of the Issuer and Chairman of the Issuer's Board of Directors, in which Dr. Yalamanchi has a pecuniary interest.  Dr. Yalamanchi disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein."}],"balance_after":113641,"source":{"system":"sec-edgar","filing":"0001140361-18-035455","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036118035455/form4.xml","form_type":"4"}},{"id":3976183,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":89713,"kind":"person","name":"Yalamanchi Naveen","position":1,"cik":"0001725743","reported_name":"Yalamanchi Naveen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-04-03T00:17:55.000Z","date":"2018-03-29","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 40,000 shares of the Issuer's Common Stock, 13,336 of which will become fully vested and exercisable on March 29, 2019, with the remaining 26,664 shares vesting in equal monthly installments over the following two years."}],"balance_after":40000,"derivative":{"exercise_price":18.75,"expiration_date":"2028-03-29","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-18-009125","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000089924318009125/doc4.xml","form_type":"4"}}]}